MitoROS contributes to DM-associated ventricular arrhythmic risk and heart failure with preserved ejection fraction (HFpEF) through oxidizing the downstream ryanodine receptor 2 (RyR2) channel and cardiac myosin binding protein C, respectively (9, 10). Here, RYR2 is linked to heart failure.